GRAL vs MD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GRAL exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical operational instability. While the company maintains an exceptionally high current ratio (11.97) and low debt, these are offset by catastrophic profit margins (-277.46%) and a bearish technical trend. Despite consistent earnings beats relative to low expectations and a 'Buy' analyst consensus, heavy insider selling ($95.49M) suggests a lack of confidence from leadership.
Pediatrix Medical Group (MD) presents a complex profile with a Piotroski F-Score of 4/9, indicating stable but mediocre financial health. While the company is significantly undervalued on a relative basis (P/E 11.50 vs Sector 73.97) and shows a highly attractive PEG ratio of 0.24, these fundamentals are countered by negative revenue growth (-1.70%) and bearish insider activity. The stock is currently trading near its Graham Number ($21.60), suggesting it is fairly valued from a defensive standpoint, despite a much higher growth-based intrinsic value of $46.75.
Compare Another Pair
Related Comparisons
GRAL vs MD: Head-to-Head Comparison
This page compares GRAIL, Inc. (GRAL) and Pediatrix Medical Group, Inc. (MD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.